Patel, H., Hubbeling, H., Yu, K., Carpenter, M., LaRiviere, M., Cohen, A., Kapur, S., Vogl, D., Waxman, A., Stadtmauer, E. and Garfall, A. Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. , Clinical Lymphoma Myeloma and Leukemia, 25: 2025,99
Cohen, A., Susanibar-Adaniya, S., Garfall, A., Vogl, D., Kapur, S., Waxman, A., Zubka, D., Hwang, W.T., Diaczynsky, C., Noll, J. and Ho, M. Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM”(Sequential T Cell-Engagement for Myeloma) Trial. , Clinical Lymphoma Myeloma and Leukemia, 25: 2025,366
Yu, K., Ho, M., Paruzzo, L., Patel, H., Ruella, M., Kapur, S., Waxman, A., Vogl, D., Cohen, A., Stadtmauer, E. and Garfall, A. Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. , Clinical Lymphoma, Myeloma and Leukemia, 25, pp.S64-S65., 25: 2025,64-65
Matthew Ho, Luca Paruzzo, Julia Noll, Federico Stella, Sonia Ndeupen, Pooja Devi, Adam Waxman, Shivani Kapur, Fang Chen, Rong Xu, Andrew Huff, Peter Michener, Vanessa Gonzalez, Dan Vogl, David Porter, Aoife Roche, John Everett, Frederic Bushman, Katherine Nathanson, Edward Stadtmauer, Sandra Susanibar-Adaniya, Alfred Garfall, Marco Ruella, Joseph Fraietta, Adam Cohen CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy. , Clinical Lymphoma Myeloma and Leukemia, 25, p.S3.
, 25(3): 2025
Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A., Ho, M., Carturan, A., Vogl, D.T., Waxman, A.J., Kapur, S., Fardella, E. and Pucillo, M. Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma. , Blood Immunology & Cellular Therapy, 1(2): 2025,100007
Paruzzo, L., Luo, T., Ho, M., Patel, H., Stella, F., Vogl, D., Kapur, S., Waxman, A., Porazzi, P., Carturan, A. and Pucillo, M. Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma—A Retrospective Evaluation. , Clinical Lymphoma Myeloma and Leukemia, 25: 2025,92-93.
Luo, T., Paruzzo, L., Susanibar Adaniya, S.P., Garfall, A.L., Ho, M., Kapur, S., Ruella, M., Stadtmauer, E.A., Stella, F., Vogl, D.T. and Waxman, A.J. Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). , Journal of Clinical Oncology, 43: 2025,7518
Vogl, D.T., Nefedova, Y., Wileyto, E.P., Whittington, S., Diaczynsky, C., Nguyen, C.T., Strakovsky, I., Bondesson, E., Tuvesson, H., Vahtola, E. and Cohen, A.D. Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM). , Journal of Clinical Oncology
, 43: 2025,7555
Ho, M., Paruzzo, L., Minehart, J., Voruganti, T., Devi, P., Vogl, D.T., Cohen, A.D., Garfall, A.L., Waxman, A.J., Kapur, S. and Stadtmauer, E.A. Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. , Haematologica, 110(6): 2025,1436-1442
Elghawy, O., Deshpande, S., Sussman, J., Garfall, A., Cohen, A., Kapur, S., Susanibar-Adaniya, S., Vogl, D., Waxman, A. and Stadtmauer, E. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. , Nature: Bone Marrow Transplantation, 60(1): 2025,64-68
